Biomarkers in Localized Prostate Cancer: Sure You Can, But Why Would You?
Alan H. Bryce, MD, discusses the role of biomarkers in clinical decision-making for localized prostate cancer. He argues that while currently available assays have demonstrated predictive ability, prospective data remains insufficient to determine whether or not they improve clinically meaningful endpoints.
Read More